Liquidia Faces Investor Probe Following Patent Ruling and Stock Slump

The inquiry centers on whether Liquidia management misled shareholders regarding the risks associated with the '327 patent litigation. During an August 12, 2026 earnings call, CEO Roger Jeffs projected that the company was on a trajectory to reach over $1 billion in net revenue by 2027. However, the company failed to clarify how an adverse court ruling might jeopardize these financial targets or impact the availability of Yutrepia for PH-ILD patients.

United Therapeutics is now seeking an injunction, potentially forcing a total removal of the product from the market. Shareholders who acquired LQDA stock prior to the disclosure of the court's decision may be eligible to pursue recovery for their losses. Levi & Korsinsky is currently evaluating claims on a contingency basis, meaning investors do not face upfront costs for the assessment. The firm is requesting that affected parties provide brokerage records, including purchase dates and quantities, to determine eligibility for participation in the investigation.